IQVIA Holdings Inc
F:QTS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
IQVIA Holdings Inc
F:QTS
|
US |
|
LG Electronics Inc
KRX:066570
|
KR |
|
G
|
Globant SA
LSE:0RIX
|
LU |
|
Galaxy Entertainment Group Ltd
OTC:GXYEF
|
HK |
|
G
|
Geo Group Inc
F:GEG
|
US |
|
P
|
Petmed Express Inc
SWB:PQM
|
US |
IQVIA Holdings Inc
IQVIA Holdings helps pharmaceutical, biotech, and medical-device companies run clinical trials, manage drug data, and analyze how medicines are used in the real world. It is best known for connecting healthcare data with research services, so drug makers can design studies, recruit patients, track outcomes, and meet regulatory requirements more efficiently. The company makes money mainly by selling research, technology, and analytics services to life sciences customers. It also licenses software and data tools that help clients plan trials, monitor safety, measure market demand, and understand physician and patient behavior. Its customers are mostly drug developers, healthcare firms, and public health organizations that need reliable data and specialized research support. IQVIA stands out because it sits between healthcare data and drug development. It does not make medicines itself; instead, it helps others test, launch, and track them. That role gives it a place throughout the life cycle of a drug, from early research to post-market analysis.
IQVIA Holdings helps pharmaceutical, biotech, and medical-device companies run clinical trials, manage drug data, and analyze how medicines are used in the real world. It is best known for connecting healthcare data with research services, so drug makers can design studies, recruit patients, track outcomes, and meet regulatory requirements more efficiently.
The company makes money mainly by selling research, technology, and analytics services to life sciences customers. It also licenses software and data tools that help clients plan trials, monitor safety, measure market demand, and understand physician and patient behavior. Its customers are mostly drug developers, healthcare firms, and public health organizations that need reliable data and specialized research support.
IQVIA stands out because it sits between healthcare data and drug development. It does not make medicines itself; instead, it helps others test, launch, and track them. That role gives it a place throughout the life cycle of a drug, from early research to post-market analysis.
Beat and raise: IQVIA said first-quarter revenue and adjusted diluted EPS both exceeded the high end of guidance, and it raised full-year adjusted EPS while reaffirming revenue and adjusted EBITDA outlooks.
Broad-based strength: Management described strong momentum in both Commercial Solutions and R&D Solutions, with organic growth accelerating in each business and backlog hitting a record.
Bookings nuance: The reported book-to-bill of 1.04x was held down by unusually low pass-through bookings, which management said had no impact on margins or underlying demand.
AI tailwind: Executives said AI is increasing client demand for IQVIA’s offerings, especially AI-ready data foundations and specialized life-science AI agents.
Outlook steady: Full-year revenue guidance of $17.150 billion to $17.350 billion and adjusted EBITDA guidance of $3.975 billion to $4.025 billion were unchanged, while second-quarter guidance pointed to continued growth.
